Company Profile

Dare Bioscience Inc (AKA: Cerulean Pharma)
Profile last edited on: 2/20/2023      CAGE: 7RNZ9      UEI: UC4EFLZHANH4

Business Identifier: Healthcare solutions for women's repro
Year Founded
2005
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3655 Nobel Drive Suite 260
San Diego, CA 92122
   (858) 926-7655
   innovations@darebioscience.com
   www.darebioscience.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Daré Bioscience, Inc., a US based clinical-stage biopharmaceutical company structured around identifying, developing, and marketing products for women's health. Only recently active nthe SBIR arena (2018-present), the firm i structured around reveloping therapies in the arenas of contraception, fertility, and sexual and vaginal health. Pproduct include XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. The firm's products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : DARE
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  Sabrina Martucci Johnson -- President and Chief Executive Officer

  David R Friend -- Chief Scientific Officer

  Roger Hawley -- Co-founder, CEO

  Christine Mauck -- Medical Director

  Elizabeth Proos

  Mark Walters -- VP of Operations

  Lisa Walters-Hoffert -- Founder and Chief Financial Officer